Skip to content
10-Q

Quarterly Report

CYTOSORBENTS CORPORATION CTSO

0001410578-25-001268

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 13, 2025 62.61M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $14.19M
Long Term Debt Q1 2025 · Dec 31, 2024 $14M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $11.59M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $3.28M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $8.61M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.74M
Current Liabilities Q1 2025 · Dec 31, 2024 $9.82M
Total Liabilities Q1 2025 · Mar 31, 2025 $36.24M
Total Liabilities Q1 2025 · Dec 31, 2024 $36.26M
Current Assets Q1 2025 · Mar 31, 2025 $25.41M
Current Assets Q1 2025 · Dec 31, 2024 $21.6M
Total Assets Q1 2025 · Mar 31, 2025 $50.78M
Total Assets Q1 2025 · Dec 31, 2024 $47.37M
Shares Diluted restated Q1 2025 · Mar 31, 2024 54.43M sh
Capex Q1 2025 · Mar 31, 2024 $45.19K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$4.83M
Stockholders Equity restated Q1 2025 · Mar 31, 2024 $19.63M
Stockholders Equity restated Q1 2025 · Dec 31, 2023 $23.48M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$0.11
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.11
Sga Expense restated Q1 2025 · Mar 31, 2024 $9.28M
Net Income restated Q1 2025 · Mar 31, 2024 −$6.09M
Operating Income restated Q1 2025 · Mar 31, 2024 −$4.66M
Gross Profit restated Q1 2025 · Mar 31, 2024 $6.87M
Cost Of Revenue restated Q1 2025 · Mar 31, 2024 $2.12M